FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2811358573> ?p ?o ?g. }

• W2811358573 endingPage "144" @default.
• W2811358573 startingPage "134" @default.
• W2811358573 abstract "Background Success of treatment withdrawal in patients with non-radiographic axial spondyloarthritis who are in remission remains unknown. The ABILITY-3 study explored the ability to withdraw adalimumab treatment in patients with non-radiographic axial spondyloarthritis who achieved sustained clinical remission after open-label treatment with adalimumab. Methods ABILITY-3 was a multicentre, two-period study done in 107 sites in 20 countries. We enrolled adult patients (≥18 years) diagnosed with non-radiographic axial spondyloarthritis, fulfilling Assessment of SpondyloArthritis international Society classification criteria but not the modified New York radiologic criterion, who had objective evidence of active inflammation, active disease, and inadequate response to at least two non-steroidal anti-inflammatory drugs. Patients who achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (<1·3) with open-label adalimumab (40 mg subcutaneously every other week for 28 weeks) at weeks 16, 20, 24, and 28 were randomly assigned (1:1) using an interactive voice or web response system to 40-week, double-blind treatment with adalimumab (continuation) or placebo (withdrawal). The primary efficacy endpoint was the proportion of patients who did not experience a flare (defined as ASDAS ≥2·1 at two consecutive visits) during the double-blind period. Patients who flared were rescued with open-label adalimumab. This study is registered with ClinicalTrials.gov, number NCT01808118. Findings Between June 27, 2013, and October 22, 2015, 673 patients were enrolled to the study. The trial completed on April 14, 2017. Of 673 enrolled patients, 305 (45%) achieved sustained remission and were randomly assigned to double-blind treatment (152 patients to adalimumab and 153 to placebo). A greater proportion of patients continuing adalimumab than those receiving placebo did not experience a flare (107 [70%] of 152 patients vs 72 [47%] of 153 patients; p<0·0001) up to and including week 68. Among 673 patients receiving adalimumab at any time, 516 (77%) patients reported an adverse event and 28 (4%) experienced a serious adverse event. The most common adverse events in both the adalimumab and placebo groups were nasopharyngitis (25 [16%] vs 20 [13%]), upper respiratory tract infection (20 [13%] vs 12 [8%]), and worsening of axial spondyloarthritis (ten [7%] vs 21 [14%]). Interpretation In patients with active non-radiographic axial spondyloarthritis who achieved sustained remission with adalimumab, continued therapy was associated with significantly fewer patients flaring than was treatment withdrawal. Funding AbbVie. Success of treatment withdrawal in patients with non-radiographic axial spondyloarthritis who are in remission remains unknown. The ABILITY-3 study explored the ability to withdraw adalimumab treatment in patients with non-radiographic axial spondyloarthritis who achieved sustained clinical remission after open-label treatment with adalimumab. ABILITY-3 was a multicentre, two-period study done in 107 sites in 20 countries. We enrolled adult patients (≥18 years) diagnosed with non-radiographic axial spondyloarthritis, fulfilling Assessment of SpondyloArthritis international Society classification criteria but not the modified New York radiologic criterion, who had objective evidence of active inflammation, active disease, and inadequate response to at least two non-steroidal anti-inflammatory drugs. Patients who achieved Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (<1·3) with open-label adalimumab (40 mg subcutaneously every other week for 28 weeks) at weeks 16, 20, 24, and 28 were randomly assigned (1:1) using an interactive voice or web response system to 40-week, double-blind treatment with adalimumab (continuation) or placebo (withdrawal). The primary efficacy endpoint was the proportion of patients who did not experience a flare (defined as ASDAS ≥2·1 at two consecutive visits) during the double-blind period. Patients who flared were rescued with open-label adalimumab. This study is registered with ClinicalTrials.gov, number NCT01808118. Between June 27, 2013, and October 22, 2015, 673 patients were enrolled to the study. The trial completed on April 14, 2017. Of 673 enrolled patients, 305 (45%) achieved sustained remission and were randomly assigned to double-blind treatment (152 patients to adalimumab and 153 to placebo). A greater proportion of patients continuing adalimumab than those receiving placebo did not experience a flare (107 [70%] of 152 patients vs 72 [47%] of 153 patients; p<0·0001) up to and including week 68. Among 673 patients receiving adalimumab at any time, 516 (77%) patients reported an adverse event and 28 (4%) experienced a serious adverse event. The most common adverse events in both the adalimumab and placebo groups were nasopharyngitis (25 [16%] vs 20 [13%]), upper respiratory tract infection (20 [13%] vs 12 [8%]), and worsening of axial spondyloarthritis (ten [7%] vs 21 [14%]). In patients with active non-radiographic axial spondyloarthritis who achieved sustained remission with adalimumab, continued therapy was associated with significantly fewer patients flaring than was treatment withdrawal." @default.
• W2811358573 created "2018-07-10" @default.
• W2811358573 creator A5001947020 @default.
• W2811358573 creator A5006822602 @default.
• W2811358573 creator A5006883657 @default.
• W2811358573 creator A5009884211 @default.
• W2811358573 creator A5010280825 @default.
• W2811358573 creator A5019054146 @default.
• W2811358573 creator A5020756974 @default.
• W2811358573 creator A5025350893 @default.
• W2811358573 creator A5038121079 @default.
• W2811358573 creator A5046013095 @default.
• W2811358573 creator A5052170557 @default.
• W2811358573 creator A5053315948 @default.
• W2811358573 creator A5062649381 @default.
• W2811358573 creator A5081778211 @default.
• W2811358573 creator A5085745432 @default.
• W2811358573 creator A5086788519 @default.
• W2811358573 date "2018-07-01" @default.
• W2811358573 modified "2023-10-12" @default.
• W2811358573 title "Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study" @default.
• W2811358573 cites W1515139043 @default.
• W2811358573 cites W1631490048 @default.
• W2811358573 cites W1967501597 @default.
• W2811358573 cites W1969936299 @default.
• W2811358573 cites W1984626603 @default.
• W2811358573 cites W2004143788 @default.
• W2811358573 cites W2066898959 @default.
• W2811358573 cites W2118072316 @default.
• W2811358573 cites W2118596556 @default.
• W2811358573 cites W2120041354 @default.
• W2811358573 cites W2147791981 @default.
• W2811358573 cites W2157270348 @default.
• W2811358573 cites W2163741803 @default.
• W2811358573 cites W2167418359 @default.
• W2811358573 cites W2170352055 @default.
• W2811358573 cites W2170715266 @default.
• W2811358573 cites W2261724355 @default.
• W2811358573 cites W2312982528 @default.
• W2811358573 cites W2342957666 @default.
• W2811358573 cites W2410851629 @default.
• W2811358573 cites W2559582708 @default.
• W2811358573 cites W2572897530 @default.
• W2811358573 cites W2604364129 @default.
• W2811358573 cites W2724955338 @default.
• W2811358573 cites W2742422772 @default.
• W2811358573 cites W2759276628 @default.
• W2811358573 cites W2765884068 @default.
• W2811358573 cites W2788828749 @default.
• W2811358573 doi "https://doi.org/10.1016/s0140-6736(18)31362-x" @default.
• W2811358573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29961640" @default.
• W2811358573 hasPublicationYear "2018" @default.
• W2811358573 type Work @default.
• W2811358573 sameAs 2811358573 @default.
• W2811358573 citedByCount "75" @default.
• W2811358573 countsByYear W28113585732018 @default.
• W2811358573 countsByYear W28113585732019 @default.
• W2811358573 countsByYear W28113585732020 @default.
• W2811358573 countsByYear W28113585732021 @default.
• W2811358573 countsByYear W28113585732022 @default.
• W2811358573 countsByYear W28113585732023 @default.
• W2811358573 crossrefType "journal-article" @default.
• W2811358573 hasAuthorship W2811358573A5001947020 @default.
• W2811358573 hasAuthorship W2811358573A5006822602 @default.
• W2811358573 hasAuthorship W2811358573A5006883657 @default.
• W2811358573 hasAuthorship W2811358573A5009884211 @default.
• W2811358573 hasAuthorship W2811358573A5010280825 @default.
• W2811358573 hasAuthorship W2811358573A5019054146 @default.
• W2811358573 hasAuthorship W2811358573A5020756974 @default.
• W2811358573 hasAuthorship W2811358573A5025350893 @default.
• W2811358573 hasAuthorship W2811358573A5038121079 @default.
• W2811358573 hasAuthorship W2811358573A5046013095 @default.
• W2811358573 hasAuthorship W2811358573A5052170557 @default.
• W2811358573 hasAuthorship W2811358573A5053315948 @default.
• W2811358573 hasAuthorship W2811358573A5062649381 @default.
• W2811358573 hasAuthorship W2811358573A5081778211 @default.
• W2811358573 hasAuthorship W2811358573A5085745432 @default.
• W2811358573 hasAuthorship W2811358573A5086788519 @default.
• W2811358573 hasConcept C126322002 @default.
• W2811358573 hasConcept C141071460 @default.
• W2811358573 hasConcept C142724271 @default.
• W2811358573 hasConcept C1862650 @default.
• W2811358573 hasConcept C197934379 @default.
• W2811358573 hasConcept C203092338 @default.
• W2811358573 hasConcept C204787440 @default.
• W2811358573 hasConcept C27081682 @default.
• W2811358573 hasConcept C2776213234 @default.
• W2811358573 hasConcept C2777402515 @default.
• W2811358573 hasConcept C2778579456 @default.
• W2811358573 hasConcept C2779134260 @default.
• W2811358573 hasConcept C2779650986 @default.
• W2811358573 hasConcept C2780132546 @default.
• W2811358573 hasConcept C535046627 @default.
• W2811358573 hasConcept C71924100 @default.
• W2811358573 hasConceptScore W2811358573C126322002 @default.
• W2811358573 hasConceptScore W2811358573C141071460 @default.
• W2811358573 hasConceptScore W2811358573C142724271 @default.
• W2811358573 hasConceptScore W2811358573C1862650 @default.

• next